Regenxbio (RGNX) Misses Q2 EPS by 47c, misses on revenue

Regenxbio (NASDAQ: RGNX) reported Q2 EPS of ($1.66), $0.47 worse than the analyst estimate of ($1.19). Revenue for the quarter came in at $19.97 million versus the consensus estimate of $34.5 million.

For earnings history and earnings-related data on Regenxbio (RGNX) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Kroger (KR) Reports In-Line Q1 EPS, Beats on Revenue; Offers FY27 EPS Guidance
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance